WO2003037276A1 - Delivery of hydrogel compositions as a fine mist - Google Patents
Delivery of hydrogel compositions as a fine mist Download PDFInfo
- Publication number
- WO2003037276A1 WO2003037276A1 PCT/US2002/030748 US0230748W WO03037276A1 WO 2003037276 A1 WO2003037276 A1 WO 2003037276A1 US 0230748 W US0230748 W US 0230748W WO 03037276 A1 WO03037276 A1 WO 03037276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- treatment temperature
- viscosity
- weight
- temperature
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/65—Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Definitions
- This invention relates to the delivery as a fine mist of dental treatment compositions having viscosities capable of responding to a change in temperature.
- the invention also relates to devices for applying the compositions as a fine mist.
- a dental treatment composition is generally desirable for numerous applications or indications including, for example, treatment of caries, calculus build-up, xerostomia, stained dentition, bad breath, gingivitis, bacterial infections, oral pain or sensitivity such as sore throat, canker sores, and burns.
- the composition be controllable and slow to flow away from it target site.
- a high viscosity dental composition in the oral environment would be quite useful.
- compositions that have very low viscosities as well as compositions that are highly thickened and therefore possess high viscosity. Those with low viscosities are difficult to control and have tendencies to flow away from the target site once it is applied. Compositions with high viscosities are difficult to extrude through a small orifice.
- compositions may use thickeners such as fumed silica and/or polymer additives such as polyvinyl alcohols, polyethylene glycols, and the like.
- Dental etching compositions which are suitable for etching hard tissue and include an acid and a thermally responsive viscosity modifier, are disclosed in PCT International Publication No. WO 00/28946.
- Dental whitening compositions that include a whitening agent and a thermally responsive viscosity modifier are disclosed in PCT International Publication No. WO 00/28955.
- Such compositions are capable of being applied to a target site through an orifice (e.g., a syringe), whereupon they undergo an increase in viscosity in response to an increase in temperature. The increase in viscosity is useful in preventing the dental compositions from flowing away from the target area of application.
- the present invention provides a method of applying a dental composition in the oral environment using an aqueous dental composition including about 10% by weight to about 50% by weight of a thermally responsive viscosity modifier and water, wherein the composition is in a low viscosity state at a pre-treatment temperature and a highly viscous state at a treatment temperature that is higher than the pre-treatment temperature.
- the method includes spraying the composition as a fine mist onto a surface, wherein the composition is at the pretreatment temperature and in the low viscosity state prior to being sprayed onto the surface, allowing the composition to warm to the treatment temperature and increase in viscosity to the highly viscous state wherein the viscosity of the composition at the treatment temperature is at least about 10 times the viscosity of the composition at the pre-treatment temperature, and allowing the composition to remain on the surface.
- the pre-treatment temperature at most about room temperature and the treatment temperature is about body temperature.
- the dental composition may optionally include adjuvants such as acids, whitening agents, fluoride sources, stability promotors, anti-microbial agents, anti-fungal agents, anti-calculus forming agents, preservatives, adhesive modifiers, fillers, dyes, detection indicators (e.g., for caries, gingivitis, and the like), cariostatic agents, flavorings, sweeteners, medicaments, sodium bicarbonate, specific enzymes, hydrating agents, and breath fresheners.
- the dental composition optionally may also include a propellant.
- the present invention provides a spray device including a container; an aqueous dental composition in the container, the composition including about 10% by weight to about 50% by weight of a thermally responsive viscosity modifier and water, wherein the composition is in a low viscosity state at a pre-treatment temperature and a highly viscous state at a treatment temperature that is higher than the pre-treatment temperature; and a sprayer in fluid communication with the dental composition, the device being capable of spraying the dental composition as a fine mist into the oral environment.
- the device may further include a propellant.
- the present invention provides a fine mist of a dental composition in the oral environment, the composition including about 10% by weight to about 50% by weight of a thermally responsive viscosity modifier and water, wherein the composition is in a low viscosity state at a pre-treatment temperature and a highly viscous state at a treatment temperature that is higher than the pre-treatment temperature.
- the present invention provides a dental composition capable of being sprayed as a fine mist into the oral environment, the composition including about 10% by weight to about 50% by weight of a thermally responsive viscosity modifier; water; and a propellant, wherein the composition is in a low viscosity state at a pre-treatment temperature and a highly viscous state at a treatment temperature that is higher than the pre-treatment temperature.
- Fig. 1 is a graphic illustration of the viscosity versus temperature data as described in Preparative Example 3.
- the present invention provides a dental composition in a low viscosity state prior to application onto an oral surface, but which also is highly viscous, thick and controllable at the target site. These compositions are easily dispensed, applied, and manipulated when handled by the user, and are easily controlled upon application to the target site. Because the composition has a low viscosity initially at a pre-treatment temperature, it is easily delivered as a fine mist to the intended site. In addition, production of low viscosity compositions may provide easier processing and greater uniformity and consistency.
- compositions of this invention are particularly suitable for use in the intraoral environment where a composition having a pre-treatment temperature at or lower than ambient (room temperature) is applied to a user's oral surface that is near or at oral temperature of about 30°C to about 39°C.
- room temperature ambient
- the composition be thermally reversible.
- the composition not only has the ability to increase its viscosity at an elevated intra-oral temperature, but also reverses or decreases its viscosity upon a decrease in temperature.
- the capacity of the dental composition to thicken at oral temperatures is a critical feature of the invention, for it is in this property that many of the disadvantages of previous approaches are overcome.
- compositions herein experience thickening at the site of treatment.
- problems of formulation, handling, delivery and application of viscous compositions are overcome since the present compositions may be free-flowing liquids prior to treatment.
- a “semi-solid,” as used herein, is a material whose physical state is between the solid and liquid state, in which pure or mixed solvent or solution is entrained within a network, and can alternatively be considered a gel.
- pure or mixed solvent and/or solution as stated herein, it is recognized that a mixture of solvents may be absorbed by the network. Additionally, the solvent may include salts or other additives so as to form a solution, which may also be absorbed or entrained within the network.
- Thickening is where a composition undergoes a substantial increase in the viscosity of the composition. The degree of thickening is dependent on the initial viscosity of the composition.
- a "fine mist” or “aerosol” means fine droplets of a liquid sprayed into the air or, alternatively, a gaseous suspension of a fine liquid and/or colloidal particles hi a preferred embodiment of the invention, the initial viscosity of the composition may be low enough such that the composition is in a liquid state.
- a composition in a liquid state may have a viscosity of about 0 to about 7000 poise.
- the viscosity of the composition can increase to at least about 10,000 poise.
- the composition preferably has the ability to reverse its viscosity and return to flow properties of a liquid.
- the pre-treatment temperature is the temperature at which the composition is subjected to prior to application or treatment.
- the range for the pre-treatment temperature can be about 5°C to about 29°C, although there may be certain instances where the temperature may be outside this range. Having a pre-treatment temperature at about 20°C to about 25°C allows the composition to be easily stored at ambient or room temperature.
- the compositions of the invention can also be advantageously stored at lower, refrigeration pre-treatment temperatures of about 5°C to about 10°C to provide improved stability and shelf life.
- the treatment temperature is the temperature at which the composition is exposed to during intraoral application. This can be at or near body temperature, or about 30°C to about 39°C.
- the dental composition consists of a water-miscible, physiologically compatible medium that is liquid at ambient temperature below about 30°C and experiences thickening at oral temperatures above about 30°C. It has been found that a composition having a thickening transition temperature in the range of from about 25°C to about 40°C is useful in the practice of the present invention. Preferably, the thickening occurs in a temperature range of from about 25°C to about 39°C, and more preferably from about 30°C to about 35°C.
- compositions of this invention are comprised of water and one or more polymeric substances that provide the desired viscosity increase at the desired elevated temperature range in the composition.
- adjuvants may be added to the composition.
- the composition of this invention should be physiologically compatible so that no adverse reaction occurs if the dental composition comes in contact with human tissue or fluids.
- a "thermally responsive viscosity modifier” is one or more polymeric substances that provide the composition or polymeric system the capability of substantially changing its viscosity in response to a change in temperature.
- Suitable polymeric substances useful as thermally responsive viscosity modifiers include polyoxyalkylene polymers, particularly the polymeric surfactants available under the tradename PLURONIC. This class of polymers is available commercially from BASF Wyandotte Corporation. Other polyoxyalkylene polymers may also be useful as a thermally-responsive composition material.
- a preferred dental composition in accordance with this invention comprises an aqueous solution of a selected polyoxyethylene-polyoxypropylene block copolymer.
- a composition comprising polyoxyethylene-polyoxypropylene block copolymers in which the number of polyoxyethylene units is at least about 50% of the number of units in the total molecule, and the block copolymer having an average molecular weight of from about 1100 to about 15,500 has been found to be particularly useful. It is more preferable that a composition comprises about 70% polyoxyethylene units of the total number of monomeric units in the copolymer and the copolymer has an average molecular weight of about 11,500.
- PLURONIC F-127 is a material that meets these criteria.
- the PLURONIC polymers are closely related block copolymers that may be generically classified as polyoxypropylene-polyoxyethylene condensates that terminate in primary hydroxyl groups. These polymers are formed by the condensation of propylene oxide into a propylene glycol nucleus followed by the condensation of ethylene oxide onto both ends of the polyoxypropylene base.
- the polyoxyethylene hydrophilic groups on the ends of the base pre-polymer are controlled in length to constitute from about 10% to about 80% by weight of the final polymer.
- the PLURONIC polymer series of products may be represented empirically by the formula: HO(C 2 H 4 ⁇ ) a (C 3 H 6 ⁇ ) b (C2 4 ⁇ ) c H where a and c are statistically equal.
- the concentration of the block copolymers is an important parameter and can be formulated in such a manner corresponding to the other components' concentrations.
- concentration of the copolymer By adjusting the concentration of the copolymer to accommodate other solutes present in the composition, any desired liquid to semi-solid transition temperature in the critical range of above ambient temperature and below body temperature can be achieved.
- the principal consideration is the selection of a concentration which, in conjunction with all of the constituents of the total composition, will provide a liquid to semi-solid transition temperature in the required range.
- a useful block copolymer concentration is from about 5% by weight to about 40% by weight (wt. %) of the composition, particularly from about 15% by weight to about 26% by weight of the composition.
- Excellent results have been obtained using aqueous solutions having from about 17% by weight to about 29% by weight of PLURONIC F-127.
- Increased polymer concentrations may be required in highly acidic systems to affect the same results as in a less acidic system so that, in optimizing the thickening or gelation characteristics for a system, the pH of the solution must be taken into account.
- Particularly preferred polymers for the present invention are the PLURONIC F-127 and F-108. These viscosity modifiers are block copolymers of ethylene oxide and propylene oxide.
- the concentration of water in the composition can be in the range of from about 30%) by weight to about 90%> by weight of the composition.
- water can exist in the range of about 40%> by weight to about 80% by weight of the composition.
- the water used in forming the aqueous solution is preferably purified, as by distillation, filtration, ion-exchange, or the like.
- Co-solvents may be used, including solutions comprising a polyol component such as propylene glycol or polyethylene glycol. Glycerin may also be used as a constituent of the composition.
- the substantial moisture content of the compositions of the present invention provides the ability to easily deliver or apply a fine mist of a gel-on- contact aqueous material that provides substantial hydration of tissues that are subject to dehydration.
- a fine mist spray or aerosol delivery it is possible to quickly and efficiently treat a relatively large surface area within the oral cavity with subsequent long-term retention upon gellation on the warm tissues.
- Other benefits include a soothing and cooling effect due to the long-term evaporation of moisture, and the ability to protect sore, ulcerated, or burned tissues with a protective aqueous gel.
- adjuvants can be added to the composition for various purposes.
- Adjuvants may include active agents and additives.
- Active agents include, but are not limited to, whitening agents, fluoride sources, antimicrobials (e.g., antibacterials), enzymes (e.g., glucose oxidase, lactoperoxidase, and lysozymes), breath fresheners, local anesthetics, clotting agents, acid neutralizers (e.g., baking soda), cariostatic agents, bleaching agents, etching agents, medicaments, anti- calculus agents, and the like.
- Particularly useful active agents for delivery as a fine mist into the oral cavity include those for hydration of xerostomic patients (i.e., drymouth), prevention and treatment of halitosis (i.e., bad breath), treatment of periodontal disease, caries reduction, and oral coatings (optionally with local anesthetics) for irritated or ulcerated tissues such as canker sores or sore throat.
- xerostomic patients i.e., drymouth
- prevention and treatment of halitosis i.e., bad breath
- treatment of periodontal disease i.e., caries reduction
- oral coatings optionally with local anesthetics
- enzymes include, for example, glucose oxidases and lactoperoxidases.
- Additives include, but are not limited to, fillers, flavorings, colorants, dyes, detection indicators (e.g., for caries, gingivitas, and the like), buffering agents, thixotropes, polyols, and the like. Additives may also be included in the composition to promote the stability of the formulation. Antimicrobial agents, antifungal agents, and preservatives may be added to the composition to improve shelf-life. Of particular interest is the application of aqueous compositions that remain localized at the desired site for extended time periods while providing the desired therapeutic effect. Especially significant is the ability to deliver thermally gellable aqueous liquids (optionally containing an adjuvant) to the oral cavity as a fine mist spray.
- the oral cavity tissues that can be treated include human and animal soft and hard tissues.
- Soft tissues include for example, mucosal and gingival tissues.
- Hard tissues include, for example, teeth and their component parts (e.g., enamel, dentin, and cementum).
- the compositions disclosed in the present application may be applied to the oral environment as a fine mist or aerosol by any suitable means known in the art (e.g.,
- compositions may be placed in a spray bottle and delivered with a hand pump.
- the compositions may be placed in a container with a propellant (e.g., air, nitrogen, carbon dioxide, and hydrocarbons) and be delivered using a pressurized spray can.
- a propellant e.g., air, nitrogen, carbon dioxide, and hydrocarbons
- the composition is passed through a fine orifice to form the fine mist.
- compositions that are useful by application as a fine mist in the oral environment are those including a peroxide.
- Dental compositions including a peroxide are useful in applications including, for example, those in which the peroxide serves as an antibacterial agent (e.g., treatment of halitosis, xerostomia, and oral infections) and the whitening of teeth.
- Preferred peroxides include hydrogen peroxide, carbamide peroxide (CO(NH ) 2 H 2 O 2 , a hydrogen peroxide urea complex), hydrogen peroxide salts (e.g., calcium salt and sodium salt), and combinations thereof. These peroxides are also known by alternative names, including urea hydrogen peroxide, hydrogen peroxide carbamide, or perhydrol-urea.
- sodium hypochlorite may be suitable in similar applications.
- Preferred concentrations of peroxide in the composition can vary depending upon its reactivity and intended use. With carbamide peroxide, for example, the preferred concentration for some applications is about 3% > to about 40%), with about 4% to about 21% being most preferred, hi the case of hydrogen peroxide, which is more reactive than carbamide peroxide, the preferred concentration for some applications is about 2%> to about 10%.
- the dental compositions are thermally reversible, the composition can be readily removed from the oral tissue by cooling the material below the liquid to semi-solid transition temperature, thus reversing the thickening effect. This can be accomplished with cool water or other physiologically compatible liquid.
- the concentrations of the components in the composition may be adjusted and diluted by adding water or other liquid solution.
- the transition temperature is correspondingly adjusted, and thus provides the user the ability to remove the composition even with warm solutions.
- Water or other liquid solutions may be administered through a rinsing cup, squirt bottle, a liquid dispensing dental tool, spray pump, aerosol, or any other liquid dispensing device that can provide solution to the oral environment.
- administering cool or cold water provides a significant decrease in viscosity.
- the gelled composition may be brushed, wiped, or blown off.
- aqueous stock solution containing approximately 15% hydrogen peroxide(H 2 O 2 ) was prepared by transferring 5 grams of a 30% H 2 O 2 (J.T. Baker) and 5 grams of distilled water to a glass vial. The stock solution was mixed thoroughly.
- aqueous stock solution containing approximately 20% urea hydrogen peroxide (carbamide peroxide) was prepared by transferring 4 grams of 97% urea hydrogen hydrogen peroxide (Sigma) and 16 grams of distilled water to a glass vial. The stock solution was mixed thoroughly. (The hydrogen peroxide content of the urea hydrogen peroxide was about 35%). Stock solution contained about 7% H 2 O 2 .
- PREPARATIVE EXAMPLE 1 A thermally-reversible hydrogen peroxide composition was prepared by transferring the ingredients below to a glass vial and mixing thoroughly until a colorless and transparent liquid solution was obtained.
- the above solution contained approximately 12%> hydrogen peroxide, 68%) water and 20%) PLURONIC F127.
- the glass vial containing the liquid peroxide solution was warmed to body temperature by holding the vial in a human hand. Following about one to two minutes, the liquid was transformed into a colorless, transparent composition that did not flow upon inverting the vial. The vial was allowed to cool to room temperature wherein the composition was transformed back to the low viscosity state. This cycle was repeated several times with the same outcome.
- the liquid and semi-solid (gel) states were both semi-quantitatively evaluated for hydrogen peroxide utilizing hydrogen peroxide analysis strips.
- the analysis utilized "EM Quant Peroxide Test Strips" (EM Science Gibbstown, New
- a thermally reversible composition containing urea hydrogen peroxide was prepared by transferring the ingredients below to a glass vial and mixing thoroughly until a colorless and transparent liquid solution was obtained.
- the above solution contained approximately 16%o urea hydrogen peroxide (or about 5.6% hydrogen peroxide), 64% water and 20% PLURONIC F127.
- the glass vial containing the liquid peroxide solution was warmed to body temperature by holding the vial in a human hand. After about 1 minute, the liquid transformed to a colorless, transparent composition that did not flow upon inverting the vial. The vial was allowed to cool to room temperature wherein the semi-solid composition was transformed back to the low viscosity state. This cycle was repeated several time with the same outcome.
- Test Strips (EM Science; Gibbstown, New Jersey, Catalog No. 10011-1), according to the manufacturer's directions. Both the liquid and semi-solid states indicated the presence of significant amounts of available peroxide.
- compositions were evaluated for viscosity as a function of temperature. The compositions are described below:
- Samples were further evaluated for viscosity as a function of temperature between 15°C and 45°C utilizing a Rheometrics RDA II Rheometer.
- Complex viscosity, ⁇ * (units of measure is in Poise), versus temperature data were obtained using a controlled strain rheometer ("RDA2", Rheometrics Scientific, Piscataway, New Jersey).
- RDA2 controlled strain rheometer
- a parallel plate geometry was used with a plate diameter of 25 mm and a gap of approximately 1 mm. Samples were subjected to an oscillatory strain of 10%) applied at a frequency of 1 rad/sec while the temperature was ramped from
- An oral hydration composition containing 18 parts PLURONIC F127 and 82 parts water was prepared by combining and thoroughly mixing the ingredients at approximately 5°C.
- the resultant homogeneous composition was a liquid at between 5°C and room temperature (e.g., about 25°C).
- the liquid was transferred to a vial fitted with hand pumped aerosol dispenser.
- the composition was easily dispensed as a fine mist at room temperature.
- the composition was sprayed onto a human hand wherein the spray gelled instantaneously on the tissue. In a similar manner, the gel could also be sprayed as a fine mist onto a surface in the oral environment.
- the hydrogel composition remained an immobile gel and provided a cooling effect over time.
- a similar, water-only solution was similarly sprayed onto the human hand wherein the liquid flowed and failed to remain localized.
- EXAMPLE 2 An oral fluoride composition containing 18 parts PLURONIC F127, 90 parts water and 1 part sodium fluoride was prepared by combimng and thoroughly mixing the ingredients at approximately 5°C.
- the resultant homogeneous composition was a liquid at between 5°C and room temperature (e.g., about 25°C).
- the liquid is transferred to a vial fitted with hand pumped aerosol dispenser.
- the composition is easily dispensed as a fine mist at room temperature.
- the composition is sprayed onto an artificial tooth heated to about 37°C wherein it forms an immobile gel on contact with the tooth.
- the liquid can be sprayed onto a tooth or into an oral cavity as a fine mist.
- An anti-bacterial, enzymatic oral hydration composition for xerostomic applications was prepared by combining 2.4 parts mouthwash available under the trade designation BIOTENE from Laclede Research Laboratories (Rancho Dominguez, CA, and containing lysozyme, lactoferrin, glucose oxidase, lactoperoxidase, water, xylitol, hydrogenated starch, propylene glycol, hydroxyethyl cellulose, aloe vera, peppermint, poloxamer 407, calcium lactate, sodium benzoate and benzoic acid), 0.9 parts PLURONIC F127, and 2.5 parts water and thoroughly mixing the ingredients at approximately 5°C.
- BIOTENE Laclede Research Laboratories
- the resultant homogeneous composition was a liquid at between 5°C and room temperature (e.g., about 25°C).
- the liquid is transferred to a vial fitted with hand pumped aerosol dispenser.
- the composition is easily dispensed as a fine mist at room temperature.
- the composition is sprayed onto an artificial tooth heated to about 37°C wherein it forms an immobile gel on contact with the tooth.
- the liquid can be sprayed onto a tooth or into an oral cavity as a fine mist.
- EXAMPLE 4 An oral liquid composition containing 18 parts PLURONIC F127, 82 parts water and 1 part sodium bicarbonate (baking soda) was prepared by combining and thoroughly mixing the ingredients at approximately 5°C.
- the resultant homogeneous composition was a liquid at between 5°C and room temperature (e.g., about 25°C).
- the liquid is transferred to a vial fitted with hand pumped aerosol dispenser.
- the composition is easily dispensed as a fine mist at room temperature.
- the composition is sprayed onto an artificial tooth heated to about 37°C wherein it forms an immobile gel on contact with the tooth.
- the liquid can be sprayed onto a tooth or into an oral cavity as a fine mist.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Dental Preparations (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60234463T DE60234463D1 (en) | 2001-11-01 | 2002-09-26 | DISTRIBUTION OF HYDROGEL COMPOSITIONS FROM FINE SPRAY |
AU2002337726A AU2002337726B2 (en) | 2001-11-01 | 2002-09-26 | Delivery of hydrogel compositions as a fine mist |
JP2003539622A JP2005507928A (en) | 2001-11-01 | 2002-09-26 | Delivery of hydrogel composition as fine mist |
CA2462826A CA2462826C (en) | 2001-11-01 | 2002-09-26 | Delivery of hydrogel compositions as a fine mist |
AT02773618T ATE448769T1 (en) | 2001-11-01 | 2002-09-26 | DELIVERY OF HYDROGEL COMPOSITIONS FROM FINE SPRAY MIST |
EP02773618A EP1439809B1 (en) | 2001-11-01 | 2002-09-26 | Delivery of hydrogel compositions as fine mist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/001,251 | 2001-11-01 | ||
US10/001,251 US6620405B2 (en) | 2001-11-01 | 2001-11-01 | Delivery of hydrogel compositions as a fine mist |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003037276A1 true WO2003037276A1 (en) | 2003-05-08 |
Family
ID=21695104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/030748 WO2003037276A1 (en) | 2001-11-01 | 2002-09-26 | Delivery of hydrogel compositions as a fine mist |
Country Status (9)
Country | Link |
---|---|
US (2) | US6620405B2 (en) |
EP (1) | EP1439809B1 (en) |
JP (1) | JP2005507928A (en) |
CN (1) | CN1582139A (en) |
AT (1) | ATE448769T1 (en) |
AU (1) | AU2002337726B2 (en) |
CA (1) | CA2462826C (en) |
DE (1) | DE60234463D1 (en) |
WO (1) | WO2003037276A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1968526A1 (en) * | 2005-12-29 | 2008-09-17 | 3M Innovative Properties Company | Foamable dental compositions and methods |
EP2441439A1 (en) | 2010-10-18 | 2012-04-18 | Luigina Straccia | Pharmacological aid for prevention of incipient carious lesion and dentinal hypersensibility |
EP2441440A1 (en) | 2010-10-18 | 2012-04-18 | Luigina Straccia | Natural pharmacological aid for prevention of periodontal inflammatory disease |
IT201800000869A1 (en) * | 2018-01-15 | 2019-07-15 | Certmedica Int Gmbh | BIOLOGICAL COMPOSITION FOR THE TREATMENT OF OSTRUCTIVE APNEE SYNDROME IN SLEEP |
US10925830B2 (en) | 2016-01-13 | 2021-02-23 | Lg Household & Health Care Ltd. | Preparation for oral cavity |
US11083671B2 (en) | 2015-11-24 | 2021-08-10 | Lg Household & Health Care Ltd. | Preparation for attaching to teeth or surrounding part of teeth |
US11981703B2 (en) | 2016-08-17 | 2024-05-14 | Sirius Therapeutics, Inc. | Polynucleotide constructs |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040151691A1 (en) * | 2003-01-30 | 2004-08-05 | Oxman Joel D. | Hardenable thermally responsive compositions |
US20040185013A1 (en) * | 2003-01-30 | 2004-09-23 | Burgio Paul A. | Dental whitening compositions and methods |
EP1706086A1 (en) * | 2004-01-21 | 2006-10-04 | 3M Innovative Properties Company | Dental compositions and kits containing bitterness inhibitors, and related methods |
US7156911B2 (en) | 2004-05-17 | 2007-01-02 | 3M Innovative Properties Company | Dental compositions containing nanofillers and related methods |
US7649029B2 (en) * | 2004-05-17 | 2010-01-19 | 3M Innovative Properties Company | Dental compositions containing nanozirconia fillers |
US20060280695A1 (en) * | 2005-06-08 | 2006-12-14 | Giles Brian C | Methods and compositions for the prevention, suppression and elimination of oral pain |
WO2009014907A1 (en) * | 2007-07-25 | 2009-01-29 | 3M Innovative Properties Company | Therapeutic dental composition and related methods |
US8329674B2 (en) * | 2007-07-25 | 2012-12-11 | 3M Innovative Properties Company | Film forming dental compositions and related methods |
US8801436B2 (en) * | 2008-04-02 | 2014-08-12 | Carson Laboraotories, I, P., Inc. | Oral hygiene composition and apparatus and method |
US8747005B2 (en) * | 2008-06-04 | 2014-06-10 | Colgate-Palmolive Company | Oral care implement with cavitation system |
US8371853B2 (en) * | 2008-10-06 | 2013-02-12 | Jbl Radical Innovations, Llc | Mouthpiece that adjusts to user arch sizes and seals from oxygen exposure and methods for effecting an oral treatment |
CA2726322C (en) * | 2010-03-18 | 2019-01-15 | Jonathan B. Levine | Mouthpiece that adjusts to user arch sizes and seals from oxygen exposure and methods for effecting an oral treatment |
US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
EP3881677A1 (en) * | 2020-03-18 | 2021-09-22 | Corticalis AS | A multi-functional cleaning and/or debridement composition |
CN114195605B (en) * | 2021-12-23 | 2022-10-11 | 中国人民解放军国防科技大学 | Hydrogen peroxide gel propellant containing metal fuel and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066566A (en) * | 1976-03-31 | 1978-01-03 | Lafant Research Company | Denture cleaner |
WO1986000813A1 (en) * | 1984-07-27 | 1986-02-13 | Schering Aktiengesellschaft | Pharmaceutical compositions containing gels |
GB2170406A (en) * | 1985-02-04 | 1986-08-06 | Colgate Palmolive Co | Oral preparation |
WO1997011675A1 (en) * | 1995-09-26 | 1997-04-03 | Colgate-Palmolive Company | Stable aqueous abrasive peroxide tooth whitening dentifrice |
WO1999011208A1 (en) * | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
WO1999032135A1 (en) * | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
WO2000028955A1 (en) * | 1998-11-12 | 2000-05-25 | Minnesota Mining And Manufacturing Company | Dental whitening composition |
WO2000028946A1 (en) * | 1998-11-12 | 2000-05-25 | Minnesota Mining And Manufacturing Company | Dental etching composition |
WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
WO2002041837A2 (en) * | 2000-11-22 | 2002-05-30 | Rxkinetix, Inc. | Treatment of mucositis |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1617744A1 (en) | 1964-07-24 | 1970-09-10 | Peter Strong & Co Inc | Cleaning agents for dentures |
US3639574A (en) | 1967-10-25 | 1972-02-01 | Basf Wyandotte Corp | Stable hydrogen peroxide gels |
US4116239A (en) * | 1974-06-14 | 1978-09-26 | Ewen Sol J | Ultrasonic oxygenation instrument |
US4011309A (en) | 1975-01-20 | 1977-03-08 | Marion Laboratories, Inc. | Dentifrice composition and method for desensitizing sensitive teeth |
US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4130501A (en) | 1976-09-20 | 1978-12-19 | Fmc Corporation | Stable viscous hydrogen peroxide solutions containing a surfactant and a method of preparing the same |
NZ204974A (en) | 1982-08-02 | 1985-10-11 | Johnson & Johnson Dental Prod | Thickened aqueous sodium fluoride compositions for dental care |
US4506803A (en) * | 1982-08-09 | 1985-03-26 | Hoffmann-La Roche Inc. | Metered aerosol dispenser and method of using the dispenser |
US4537778A (en) | 1983-01-03 | 1985-08-27 | Colgate-Palmolive Company | Oral preparation |
JPS59128330A (en) | 1983-01-06 | 1984-07-24 | Kuraray Co Ltd | Dental acid treatment |
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4950479A (en) * | 1986-11-06 | 1990-08-21 | Hill Ira D | Method of interrupting the formation of plaque |
US4774093A (en) | 1985-06-25 | 1988-09-27 | Fmc Corporation | Polysaccharide compositions, preparation and uses |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
US5053000A (en) * | 1985-11-13 | 1991-10-01 | Imperial Chemical Industries Plc | Ocular treatment |
GB8528032D0 (en) * | 1985-11-13 | 1985-12-18 | Ici Plc | Ocular treatment |
GB8604328D0 (en) * | 1986-02-21 | 1986-03-26 | Ici Plc | Producing spray of droplets of liquid |
US4719149A (en) | 1986-02-28 | 1988-01-12 | Minnesota Mining And Manufacturing Company | Method for priming hard tissue |
US4770634A (en) | 1986-06-11 | 1988-09-13 | Pellico Michael A | Method for treating teeth with foamable fluoride compositions |
US4696757A (en) | 1986-06-16 | 1987-09-29 | American Home Products Corporation | Stable hydrogen peroxide gels |
GB8624670D0 (en) * | 1986-10-15 | 1986-11-19 | Glaxo Group Ltd | Valve for aerosol container |
US5057308A (en) | 1986-11-06 | 1991-10-15 | Hill Ira D | Method of treating the oral cavity with oral hygiene preparations containing active SnF2 |
US5032387A (en) * | 1986-11-06 | 1991-07-16 | Princeton Pharmaceutical Inc. | Dental and oral hygiene preparations |
US5057310A (en) | 1986-11-06 | 1991-10-15 | Hill Ira D | Method of manufacturing oral hygiene preparations containing active SnF.sub. |
US5057309A (en) | 1986-11-06 | 1991-10-15 | Hill Ira D | Oral hygiene preparations |
US5575652A (en) | 1987-01-30 | 1996-11-19 | Colgate Palmolive Company | Process for applying antibacterial oral composition to dental implant areas |
GB2203039B (en) | 1987-03-02 | 1990-10-24 | American Cyanamid Co | Stable ophthalmic preparations containing acetazolamide |
US4839156A (en) | 1987-04-17 | 1989-06-13 | Colgate-Palmolive Company | Stable hydrogen peroxide dental gel |
US5078129A (en) | 1987-05-01 | 1992-01-07 | Research Foundation Of State University Of New York | Device for stimulating salivation |
US4980152A (en) | 1987-08-06 | 1990-12-25 | Marion Laboratories | Oral preparation |
US4978336A (en) * | 1987-09-29 | 1990-12-18 | Hemaedics, Inc. | Biological syringe system |
US4795527A (en) | 1987-12-07 | 1989-01-03 | Howard Cohen | Tooth etching |
US4895721A (en) | 1988-01-22 | 1990-01-23 | Carter-Wallace Inc. | Peroxide gel dentifrice compositions |
DE3810262A1 (en) * | 1988-03-25 | 1989-10-12 | Henning Berlin Gmbh | DEVICE FOR THE DOSED ADMINISTRATION OF A LIQUID MEDICINAL PRODUCT |
US5000955A (en) | 1988-07-29 | 1991-03-19 | Tyndale Plains-Hunter Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
WO1990009165A1 (en) | 1989-02-15 | 1990-08-23 | Murayama Ronald K | Teeth whitener |
US4921626A (en) | 1989-08-23 | 1990-05-01 | Automark Corporation | Glass etching composition and method of making |
US5116315A (en) * | 1989-10-03 | 1992-05-26 | Hemaedics, Inc. | Biological syringe system |
US5073363A (en) | 1989-10-06 | 1991-12-17 | Pellico Michael A | Foamable fluoride gels and method |
US5071637A (en) | 1989-10-06 | 1991-12-10 | Pellico Michael A | Foamable fluoride compositions and method |
DE58906847D1 (en) | 1989-11-10 | 1994-03-10 | Thor Chemie Gmbh | Stabilized aqueous solutions of 3-isothiazolinones. |
US5256065A (en) | 1989-11-13 | 1993-10-26 | Nicholson James A | Acid etch for dental treatments |
US5061183A (en) | 1989-11-13 | 1991-10-29 | Nicholson James A | Acid etch for bonding ceramic orthodontic brackets |
US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
US5234342A (en) | 1990-03-22 | 1993-08-10 | Ultradent Products, Inc. | Sustained release method for treating teeth surfaces |
US5098303A (en) | 1990-03-22 | 1992-03-24 | Ultradent Products, Inc. | Method for bleaching teeth |
US5376006A (en) | 1990-03-22 | 1994-12-27 | Ultradent Products, Inc. | Dental bleaching compositions and methods for bleaching teeth surfaces |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
US5059417A (en) | 1990-06-26 | 1991-10-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Peroxide gel dentifrice |
US5124151A (en) | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
US5376693A (en) | 1990-08-07 | 1994-12-27 | Mediventures Inc. | Thermo-irreversible gel corneal contact lens formed in situ |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
US5401495A (en) | 1990-10-10 | 1995-03-28 | Natural White, Inc. | Teeth whitener |
US5847023A (en) | 1990-10-26 | 1998-12-08 | Mdv Technologies, Inc. | Thermal irreversible gel corneal contact lens formed in situ |
SE466134B (en) | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | GEL-PHARMACEUTICAL LIQUID COMPOSITION AND APPLICATION THEREOF IN PHARMACEUTICAL COMPOSITIONS |
US5277175A (en) * | 1991-07-12 | 1994-01-11 | Riggs John H | Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir |
AU660691B2 (en) | 1991-09-13 | 1995-07-06 | Colgate-Palmolive Company, The | Abrasive tooth whitening dentifrice of improved stability |
US5171564A (en) | 1991-09-13 | 1992-12-15 | Colgate-Palmolive | Aqueous tooth whitening dentifrice |
US5279816A (en) | 1991-11-22 | 1994-01-18 | Colgate-Palmolive Co. | Oral composition having improved tooth whitening effect |
US5374396A (en) * | 1992-05-05 | 1994-12-20 | Tsi Incorporated | Syringe injection system for measuring non-volatile residue in solvents |
US5340613A (en) | 1993-03-12 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Process for simultaneously coating multiple layers of thermoreversible organogels and coated articles produced thereby |
US5409630A (en) | 1994-02-03 | 1995-04-25 | Colgate Palmolive Co. | Thickened stable acidic microemulsion cleaning composition |
WO1996002577A1 (en) | 1994-07-18 | 1996-02-01 | Gel Sciences, Inc. | Responsive polymer gel beads |
AU3274895A (en) | 1994-07-18 | 1996-02-16 | Gel Sciences, Inc. | Novel polymer gel networks and methods of use |
AU3410695A (en) | 1994-08-19 | 1996-03-14 | Gel Sciences, Inc. | Responsive gels for selective removal of a target from an environment and methods therefor |
US5861148A (en) | 1995-01-23 | 1999-01-19 | Smith; Stewart Gregory | Ophthalmic compositions and process of using |
US5849412A (en) | 1995-02-17 | 1998-12-15 | Medlogic Global Corporation | Encapsulated materials |
WO1996028056A1 (en) | 1995-03-15 | 1996-09-19 | Gel Sciences, Inc. | Conformable structures |
WO1997000275A2 (en) | 1995-06-16 | 1997-01-03 | Gel Sciences, Inc. | Responsive polymer networks and methods of their use |
US5866632A (en) | 1995-08-10 | 1999-02-02 | Sun Medical Co., Ltd. | Dental or surgical adhesive and polymerization initiator composition for the same |
US6350123B1 (en) * | 1995-08-31 | 2002-02-26 | Biolase Technology, Inc. | Fluid conditioning system |
DE69631490T2 (en) * | 1995-11-09 | 2004-10-07 | Univ Massachusetts Boston | RESTORATION OF TISSUE SURFACE WITH COMPOSITIONS FROM HYDROGEL CELLS |
US5766574A (en) | 1995-12-08 | 1998-06-16 | Colgate Palmolive Company | Dual component tooth whitening dentifrice |
US5631000A (en) | 1996-03-11 | 1997-05-20 | Laclede Professional Products, Inc. | Anhydrous tooth whitening gel |
US5718886A (en) | 1996-03-11 | 1998-02-17 | Laclede Professional Products, Inc. | Stabilized anhydrous tooth whitening gel |
US5814304A (en) | 1996-08-02 | 1998-09-29 | Colgate Palmolive Company | Stable aqueous abrasive peroxide tooth whitening dentifrice |
US5858332A (en) | 1997-01-10 | 1999-01-12 | Ultradent Products, Inc. | Dental bleaching compositions with high concentrations of hydrogen peroxide |
US5902568A (en) | 1997-01-15 | 1999-05-11 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method for whitening teeth |
US5819988A (en) | 1997-04-01 | 1998-10-13 | Sawhney; Ravi K. | Double-barreled syringe with detachable locking mixing tip |
US5766012A (en) | 1997-04-28 | 1998-06-16 | Rosenbaum; Michael | Dental etchant and process of using |
US5846570A (en) | 1997-06-27 | 1998-12-08 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Stabilized hydrogen peroxide gel compositions |
US5928628A (en) | 1997-10-23 | 1999-07-27 | Pellico; Michael A. | Two-component dental bleaching system and method |
US6116900A (en) | 1997-11-17 | 2000-09-12 | Lumachem, Inc. | Binary energizer and peroxide delivery system for dental bleaching |
US6126443A (en) | 1998-08-13 | 2000-10-03 | 3M Innovative Properties Company | Medication delivery tray |
US6669927B2 (en) * | 1998-11-12 | 2003-12-30 | 3M Innovative Properties Company | Dental compositions |
US20040033260A1 (en) * | 1999-10-19 | 2004-02-19 | The Procter & Gamble Company | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
-
2001
- 2001-11-01 US US10/001,251 patent/US6620405B2/en not_active Expired - Lifetime
-
2002
- 2002-09-26 CA CA2462826A patent/CA2462826C/en not_active Expired - Fee Related
- 2002-09-26 JP JP2003539622A patent/JP2005507928A/en active Pending
- 2002-09-26 CN CNA028218523A patent/CN1582139A/en active Pending
- 2002-09-26 AU AU2002337726A patent/AU2002337726B2/en not_active Ceased
- 2002-09-26 AT AT02773618T patent/ATE448769T1/en not_active IP Right Cessation
- 2002-09-26 DE DE60234463T patent/DE60234463D1/en not_active Expired - Lifetime
- 2002-09-26 EP EP02773618A patent/EP1439809B1/en not_active Expired - Lifetime
- 2002-09-26 WO PCT/US2002/030748 patent/WO2003037276A1/en active IP Right Grant
-
2003
- 2003-07-16 US US10/620,548 patent/US20040013612A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066566A (en) * | 1976-03-31 | 1978-01-03 | Lafant Research Company | Denture cleaner |
WO1986000813A1 (en) * | 1984-07-27 | 1986-02-13 | Schering Aktiengesellschaft | Pharmaceutical compositions containing gels |
GB2170406A (en) * | 1985-02-04 | 1986-08-06 | Colgate Palmolive Co | Oral preparation |
WO1997011675A1 (en) * | 1995-09-26 | 1997-04-03 | Colgate-Palmolive Company | Stable aqueous abrasive peroxide tooth whitening dentifrice |
WO1999011208A1 (en) * | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
WO1999032135A1 (en) * | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
WO2000028955A1 (en) * | 1998-11-12 | 2000-05-25 | Minnesota Mining And Manufacturing Company | Dental whitening composition |
WO2000028946A1 (en) * | 1998-11-12 | 2000-05-25 | Minnesota Mining And Manufacturing Company | Dental etching composition |
WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
WO2002041837A2 (en) * | 2000-11-22 | 2002-05-30 | Rxkinetix, Inc. | Treatment of mucositis |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1968526A1 (en) * | 2005-12-29 | 2008-09-17 | 3M Innovative Properties Company | Foamable dental compositions and methods |
EP1968526A4 (en) * | 2005-12-29 | 2009-10-28 | 3M Innovative Properties Co | Foamable dental compositions and methods |
EP2441439A1 (en) | 2010-10-18 | 2012-04-18 | Luigina Straccia | Pharmacological aid for prevention of incipient carious lesion and dentinal hypersensibility |
EP2441440A1 (en) | 2010-10-18 | 2012-04-18 | Luigina Straccia | Natural pharmacological aid for prevention of periodontal inflammatory disease |
ITMC20100100A1 (en) * | 2010-10-18 | 2012-04-19 | Luigina Straccia | PHARMACOLOGICAL PRESIDIUM FOR THE PREVENTION OF CARIOUS INCIRIENT LESION AND DENTAL HYPERSENSITIVITY. |
ITMC20100101A1 (en) * | 2010-10-18 | 2012-04-19 | Luigina Straccia | NATURAL PHARMACOLOGICAL PRESIDIUM FOR THE PREVENTION OF INFLAMMATORY DISEASES OF PARODONTO. |
US11083671B2 (en) | 2015-11-24 | 2021-08-10 | Lg Household & Health Care Ltd. | Preparation for attaching to teeth or surrounding part of teeth |
US10925830B2 (en) | 2016-01-13 | 2021-02-23 | Lg Household & Health Care Ltd. | Preparation for oral cavity |
US11872310B2 (en) | 2016-01-13 | 2024-01-16 | Lg Household & Health Care Ltd. | Preparation for oral cavity |
US11981703B2 (en) | 2016-08-17 | 2024-05-14 | Sirius Therapeutics, Inc. | Polynucleotide constructs |
IT201800000869A1 (en) * | 2018-01-15 | 2019-07-15 | Certmedica Int Gmbh | BIOLOGICAL COMPOSITION FOR THE TREATMENT OF OSTRUCTIVE APNEE SYNDROME IN SLEEP |
Also Published As
Publication number | Publication date |
---|---|
JP2005507928A (en) | 2005-03-24 |
DE60234463D1 (en) | 2009-12-31 |
US20030103911A1 (en) | 2003-06-05 |
CA2462826C (en) | 2012-01-31 |
US20040013612A1 (en) | 2004-01-22 |
US6620405B2 (en) | 2003-09-16 |
CN1582139A (en) | 2005-02-16 |
ATE448769T1 (en) | 2009-12-15 |
EP1439809B1 (en) | 2009-11-18 |
CA2462826A1 (en) | 2003-05-08 |
EP1439809A1 (en) | 2004-07-28 |
AU2002337726B2 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6620405B2 (en) | Delivery of hydrogel compositions as a fine mist | |
AU2002337726A1 (en) | Delivery of hydrogel compositions as a fine mist | |
US6312666B1 (en) | Methods of whitening teeth | |
US6669927B2 (en) | Dental compositions | |
JP2694166B2 (en) | Gel forming liquid carrier composition | |
CA2887505C (en) | Remineralizing and desensitizing compositions, treatments and methods of manufacture | |
JPH04210907A (en) | Topical application composition | |
US6312667B1 (en) | Methods of etching hard tissue in the oral environment | |
CN116437897A (en) | Oral hydrogel composition and use | |
CN112121157A (en) | Composition based on enhanced vitamin D3, oral care gel and application thereof | |
JP2001507708A (en) | Use of dichlorobenzyl alcohol for preparing formulations for topical treatment of inflammation and formulations containing dichlorobenzyl alcohol | |
JP2009500303A (en) | Composition for oral cavity containing dimethicone copolyol | |
EP4120992B1 (en) | Composition | |
DK2117502T3 (en) | COMPOSITION TO FIGHT EPISTAXIS | |
EP4378490A1 (en) | Haemostatic composition | |
WO2024118019A1 (en) | Dermal thermosensitive gel formulations for the treatment of inflammation-related edema and various pains | |
GB2375048A (en) | Formulation | |
JP2003119129A (en) | Benzalkonium chloride-containing gel-like external preparation | |
KR20010001116A (en) | Slow drug released toothpaste composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002773618 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2462826 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002337726 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003539622 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028218523 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002773618 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002337726 Country of ref document: AU |